Attorney Mistake Dooms Angiomax Patent Extension

Law360, New York (December 11, 2006, 12:00 AM EST) -- The Medicines Co. disclosed Monday that the U.S. Patent and Trademark Office has rejected its application to extend its patent on the blood thinning drug Angiomax.

In papers filed with the Securities and Exchange Commission, the Medicines Co. blamed its attorneys, saying the application was shot down because its counsel did not hand it in on time.

The patent for Angiomax currently expires in 2010, but the Parsippany, N.J.-based pharmaceutical company was hoping to push the expiration date forward to 2014.

In February 2001, lawyers for...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.